Press releaseGlobe Newswire
Beyondspring
BYSI · NASDAQ
$0.5227+$0.0098 (+1.91%)TodayMarket closed ·
Prev close $0.5129
Latest news
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
BeyondSpring Files 2025 Annual Report on Form 10-K
- Press releaseGlobe Newswire
BeyondSpring Reports 2025 Year-End Financial Results
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
- Press releaseGlobe Newswire
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
- Press releaseGlobe Newswire
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
BeyondSpring Files 2024 Annual Report on Form 10-K
- Press releaseGlobe Newswire
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.